Soligenix Inc (OTCBB - OTCQB:SNGX)

2.30
Delayed Data
As of Jul 02
 0.00 / 0.00%
Today’s Change
0.91
Today|||52-Week Range
2.95
+134.81%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$60.4M

Company Description

Soligenix, Inc. is a clinical stage biopharmaceutical company. It is focused on developing products to treat serious gastrointestinal diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics. The company operates through BioTherapeutics and Vaccines/BioDefense segments. The BioTherapeutics segment intends to develop oral beclomethasone dipropionate indications such as pediatric crohn's disease and acute radiation enteritis. The Vaccines/BioDefense segment includes active development programs for RiVax, its ricin toxin vaccine, and VeloThrax, its anthrax vaccine, and OrbeShield, its gastrointestinal acute radiation syndrome therapeutic. Soligenix was founded in 1987 and is headquartered Princeton, NJ.

Contact Information

Soligenix, Inc.
29 Emmons Drive
Princeton New Jersey 08540-5919
P:(609) 538-8200
Investor Relations:

Employees

Shareholders

Individual stakeholders18.08%
Mutual fund holders--
Other institutional--

Top Executives

Christopher J. SchaberChairman, President & Chief Executive Officer
Joseph Michael WaruszChief Financial Officer, Secretary & VP
Oreola DoniniChief Scientific Officer & Senior Vice President
Richard C. StraubeChief Medical Officer & Senior Vice President
Rasappa ArumughamVice President-Biopharmaceutical Development

To view my watchlist

Not a member yet?

Sign up now for a free account